DBV TECHNOLOGIE/S (DBVT) Given Consensus Recommendation of “Buy” by Analysts
Shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) have earned an average rating of “Buy” from the twelve ratings firms that are covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $39.20.
Several research firms have weighed in on DBVT. Stifel Nicolaus began coverage on DBV TECHNOLOGIE/S in a research note on Thursday. They issued a “buy” rating for the company. BidaskClub upgraded DBV TECHNOLOGIE/S from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 28th. ValuEngine upgraded DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a research note on Thursday, August 2nd. Morgan Stanley dropped their price target on DBV TECHNOLOGIE/S from $28.00 to $27.00 and set an “equal weight” rating for the company in a research note on Tuesday. Finally, Zacks Investment Research downgraded DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating in a research note on Friday, June 1st.
DBVT stock traded up $0.28 during midday trading on Friday, hitting $23.81. The company’s stock had a trading volume of 149,900 shares, compared to its average volume of 201,396. DBV TECHNOLOGIE/S has a 12 month low of $16.65 and a 12 month high of $50.57. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.37 and a quick ratio of 4.37. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -7.24 and a beta of 1.05.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Featured Article: Fundamental Analysis
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.